AARDEX Group

Important milestone in managing adherence to anti-osteoporosis treatment

AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.

AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.

Great team of experts who met to define a strong consensus under the auspices of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing.

Publication title:
Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)

Journal: Osteoporosis International, 30(11), 2155-2165

DOI: 10.1007/s00198-019-05104-5

Access the publication here

Share This Post

You may also like...

Breaking News

Enhancing Medication Adherence in Rare Disease Clinical Trials

In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected